ABBV

AbbVie Inc.

142.46 USD
+3.96 (+2.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AbbVie Inc. stock is up 0.91% since 30 days ago. The dividend yield is 4.27% and its next earnings date is Feb 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 10 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Nov 14:51 17 May, 2024 140.00 CALL 39 2496
30 Nov 14:52 17 May, 2024 140.00 PUT 31 3015
30 Nov 15:46 21 Jun, 2024 150.00 CALL 90 2316
30 Nov 15:47 17 Jan, 2025 155.00 CALL 50 2669
30 Nov 16:03 15 Dec, 2023 145.00 PUT 59 3583
30 Nov 16:13 16 Jan, 2026 160.00 CALL 26 49
30 Nov 17:01 15 Mar, 2024 135.00 PUT 82 907
30 Nov 17:04 16 Feb, 2024 140.00 CALL 82 1203
30 Nov 18:06 16 Feb, 2024 155.00 CALL 538 1451
30 Nov 18:47 17 Jan, 2025 145.00 CALL 22 10248

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.